NCT02099266

Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment

A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: University of Kansas Medical Center · Academic / Other
• Sex: All
• Age: 17 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

By doing this study, researchers hope to learn the following: * If providing hyperbaric oxygen (HBO) therapy prior to an umbilical cord blood (UBC) transplant will help to improve the homing process * The safety of HBO administration in the setting of the UBC transplant * The effects of HBO therapy on the engraftment process

Detailed description

Research has suggested that high levels of erythropoietin (EPO) decreases the ability of infused umbilical cord stem cells to home to the bone marrow. The investigators will investigate the use of hyperbaric oxygen (HBO) therapy to decrease the plasma concentrations of EPO prior to UBC transplant and evaluate the resulting impact on UBC homing.

Conditions

• Acute Myeloid Leukemia
• Acute Lymphoblastic Leukemia
• Myelodysplastic Syndrome (MDS)
• Hodgkins Lymphoma
• Non-Hodgkins Lymphoma

Interventions

Type	Name	Description
DEVICE	Administration of hyperbaric oxygen	Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours

Timeline

• Start date: 2013-06-01
• Primary completion: 2015-10-01
• Completion: 2016-02-01
• First posted: 2014-03-28
• Last updated: 2017-06-12
• Results posted: 2017-03-17

Locations

1 site across 1 country: United States